Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is no effective pharmacologic treatment for NAFLD. FABP1 is a liver‐specific fatty acid‐binding protein (FABP) that plays...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukai, Takako, Egawa, Miki, Takeuchi, Tamaki, Yamashita, Hitoshi, Kusudo, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494302/
https://www.ncbi.nlm.nih.gov/pubmed/28680813
http://dx.doi.org/10.1002/2211-5463.12240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494302/
https://www.ncbi.nlm.nih.gov/pubmed/28680813
http://dx.doi.org/10.1002/2211-5463.12240

Ejemplares similares